New late-stage Bydureon data fail to impress
This article was originally published in Scrip
Executive Summary
Amylin, Lilly and Alkermes' Bydureon (once-weekly exenatide) was superior as a monotherapy to Merck & Co's Januvia (sitagliptin) in improving HbA1c levels, but failed to beat Takeda's Actos (pioglitazone) or metformin, show top-line DURATION-4 results. Analysts were unimpressed with the results.